Table 1.
Characteristics of patients with invasive pulmonary aspergillosis (IPA) and control patients who had bronchoalveolar lavage fluid samples tested with the Aspergillus galactomannan lateral flow assay.
| IPA Cases (n = 20) No. (%) |
Controls (n = 20) No. (%) |
|
|---|---|---|
| Mean age (years ± SD) | 55.1 ± 17.4 | 55.1 ± 17.1 |
| Female | 8 (40) | 8 (40) |
| Host factors for invasive Aspergillosis 1 | ||
| Solid organ transplant | 9 (45) | 9 (45) |
| Lung transplant | 9 | 6 |
| Liver transplant | 0 | 2 |
| Kidney transplant | 0 | 1 |
| High dose corticosteroids 2 | 4 (20) | 4 (20) |
| Hematologic malignancy | 5 (25) | 4 (20) |
| Chronic pulmonary disease | 2(10) | 1 (5) |
| HIV <200 CD4/μL | 1 (5) | 1 (5) |
| Critical illness | 2 (10) | 2 (10) |
| Additional features | ||
| Mold-active antifungal exposure 3 | 1 (5) | 0 |
1 Several patients had more than one host factor; 2 dose equivalent to ≥0.3 mg/kg prednisone daily for ≥3 weeks at the time of bronchoscopy; 3 receipt of mold-active antifungal agent within 5 days prior to bronchoscopy.